Pharmaceutical News

RSS

Study: Synthetic triglyceride oil may provide hope for people with Huntington's disease

An early study suggests that a synthetic triglyceride oil called triheptanoin may provide hope for people with Huntington's disease. The study is published in the January 7, 2015, online issue of Neurology, the medical journal of the American Academy of Neurology.

7 Jan 2015

Kyowa Hakko Kirin and Syndax sign agreement to develop entinostat in Japan and Korea

Kyowa Hakko Kirin Co., Ltd., (Headquarters: Chiyoda-ku, Tokyo; president and CEO: Nobuo Hanai, "Kyowa Hakko Kirin") and Syndax Pharmaceuticals, Inc., (Waltham, Mass.; president and CEO: Arlene M. Morris, "Syndax") today jointly announced that the companies have entered into a license agreement for the exclusive rights to develop and commercialize entinostat in Japan and Korea.

7 Jan 2015

Soligenix's SGX301 receives FDA 'Fast Track' designation for CTCL treatment

Soligenix, Inc., a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that its SGX301 (synthetic hypericin) development program for the first-line treatment of cutaneous T-cell lymphoma (CTCL) has received "Fast Track" designation from the US Food and Drug Administration.

7 Jan 2015

Certain patients with type 2 diabetes, renal impairment discouraged from taking metformin

Many patients with type 2 diabetes in the United States may be discouraged from taking metformin—a proven, oral diabetes medicine—because the U.S. Food and Drug Administration inappropriately labels the drug unsafe for some patients also suffering from kidney problems, researchers from Penn Medicine and Weill Cornel Medical College report this week in a research letter published in JAMA Internal Medicine.

7 Jan 2015

LSNE's Harvey Road facility receives approval to manufacture drug product for US distribution

Lyophilization Services of New England, Inc. announced today that following an FDA Pre-Approval Inspection (PAI) in November 2014, their Harvey Road manufacturing site has received approval to manufacture commercial drug product for US distribution.

7 Jan 2015

Gamida Cell granted FDA and EMA orphan drug designation for NiCord

Gamida Cell, a leader in cell therapy technologies and products for transplantation and adaptive immune therapy, announced today that orphan drug designation has been granted by The US Department of Health and Human Services, The FDA Office of Orphan Products Development (OOPD) for the investigational medicinal product NiCord for the treatment of acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), Hodgkin lymphoma and myelodysplastic syndrome (MDS).

6 Jan 2015

Most Americans unaware of the positive benefits of folic acid

Each year, more than four million women in America give birth and 2,600 infants are born with neural tube defects.

6 Jan 2015

Oncoceutics, MD Anderson partner to develop novel anti-cancer drug

Oncoceutics Inc. and The University of Texas MD Anderson Cancer Center today announced the initiation of a strategic alliance and research collaboration agreement for the clinical development of ONC201, a novel anti-cancer drug.

5 Jan 2015

Vitamin B counteracts levels of DDT in women who are more likely to get, stay pregnant

Women who have adequate levels of B vitamins in their bodies are more likely to get and stay pregnant even when they also have high levels of a common pesticide known to have detrimental reproductive effects, according to new Johns Hopkins Bloomberg School of Public Health research.

5 Jan 2015

Study confirms safety of two measles-containing vaccines

A 12-year study of two measles-containing vaccines, published today in Pediatrics, found that seven main adverse outcomes were unlikely after either vaccine.

5 Jan 2015

Clementia secures additional $10 million to support development of palovarotene for treatment of FOP

Clementia Pharmaceuticals, Inc. today announced that it has secured an additional $10 million from current investors to support development of the company's lead compound palovarotene for the treatment of fibrodysplasia ossificans progressive (FOP).

5 Jan 2015

Sirnaomics submits STP705 IND Application to CFDA for skin scar treatment

Sirnaomics, Inc. and its affiliate Suzhou Sirnaomics Pharmaceutics, Co. Ltd., together with its partner Guangzhou Xiangxue Pharmaceutical, Co. Ltd., (SZSE: 300147), have formally submitted an Investigational New Drug (IND) Application to the China Food and Drug Administration for STP705, an anti-fibrosis RNA interference (RNAi) therapeutic for prevention and treatment of human skin hypertrophic scars.

5 Jan 2015

TxCell announces further enhancement to development of Ovasave for IBD treatment

Paulsen Foundation to provide specialist management and scientific and development expertise that is dedicated to advanced therapies, i.e. cellular and gene therapies. This new class of highly promising biological therapies includes TxCell’s Ovasave.

5 Jan 2015

Saatchi Bill: an interview with Dr. David Collingridge, Editor-in-Chief, The Lancet Oncology

The intention of the Medical Innovation Bill is to encourage and support doctors to explore new medicines for their patients when they believe existing options are no longer achieving good outcomes.

4 Jan 2015

Combination of bedaquiline and verapamil reduces side effects, improves outcomes for TB patients

While an effective treatment is available for combating multidrug-resistant tuberculosis, it carries serious side effects for patients.

31 Dec 2014

Sex enhancement product recalled after Health Canada test finds undeclared drug ingredient

One lot of the sex enhancement product "Forta for Men" (NPN 80045132) is being recalled after Health Canada testing confirmed it contains an undeclared drug: homosildenafil.

31 Dec 2014

Tikcro enters into research and license agreement with Yeda

Tikcro Technologies Ltd. today announced that it has entered into a research and license agreement with Yeda Research and Development Company Ltd., the technology transfer arm of the Weizmann Institute of Science in Israel.

30 Dec 2014

FDA approves Hospira's Dyloject (diclofenac sodium) Injection for pain management

Hospira, Inc., the world's leading provider of injectable drugs and infusion technologies, and a global leader in biosimilars, has received approval from the U.S. Food and Drug Administration for Dyloject (diclofenac sodium) Injection, a proprietary nonsteroidal anti-inflammatory drug (NSAID) analgesic.

30 Dec 2014

Early use of heart failure drugs slows cardiac damage in boys, young men with DMD

Early use of available heart failure drugs slows the progressive decline in heart function before symptoms are apparent in boys and young men with Duchenne muscular dystrophy (DMD), according to a new study published online by The Lancet Neurology.

30 Dec 2014

Janssen, Gilead to jointly develop darunavir-based, single-tablet regimen for HIV treatment

Janssen R&D Ireland announced today an amendment to its existing agreement with Gilead Sciences, Inc., initially established in 2011, for the development of a once daily, darunavir-based, single-tablet regimen (STR) for the treatment of people living with HIV.

29 Dec 2014

Pharmaceutical News

Study: Synthetic triglyceride oil may provide hope for people with Huntington's disease

Kyowa Hakko Kirin and Syndax sign agreement to develop entinostat in Japan and Korea

Soligenix's SGX301 receives FDA 'Fast Track' designation for CTCL treatment

Certain patients with type 2 diabetes, renal impairment discouraged from taking metformin

LSNE's Harvey Road facility receives approval to manufacture drug product for US distribution

Gamida Cell granted FDA and EMA orphan drug designation for NiCord

Most Americans unaware of the positive benefits of folic acid

Oncoceutics, MD Anderson partner to develop novel anti-cancer drug

Vitamin B counteracts levels of DDT in women who are more likely to get, stay pregnant

Study confirms safety of two measles-containing vaccines

Clementia secures additional $10 million to support development of palovarotene for treatment of FOP

Sirnaomics submits STP705 IND Application to CFDA for skin scar treatment

TxCell announces further enhancement to development of Ovasave for IBD treatment

Saatchi Bill: an interview with Dr. David Collingridge, Editor-in-Chief, The Lancet Oncology

Combination of bedaquiline and verapamil reduces side effects, improves outcomes for TB patients

Sex enhancement product recalled after Health Canada test finds undeclared drug ingredient

Tikcro enters into research and license agreement with Yeda

FDA approves Hospira's Dyloject (diclofenac sodium) Injection for pain management

Early use of heart failure drugs slows cardiac damage in boys, young men with DMD

Janssen, Gilead to jointly develop darunavir-based, single-tablet regimen for HIV treatment

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Latest News